Role of Chlamydia in the Development of Ocular Adnexal Lymphoma


The aetiology of OAL is undefined, although much attention has been recently focused on determining whether OAL is caused by an autoimmune disorder, chronic antigenic stimulation or both. It is becoming evident that infectious agents underlying chronic eye infection, as Chlamydia, may play a role in ocular lymphomagenesis. The high prevalence of Chlamydophila psittaci in patients with OAL has suggested a potential oncogenic role for its tendency to cause chronic and persistent infections, although it has been documented an evident geographical variability and response to antibiotic treatment. For C. pneumoniae, the findings so far obtained are very limited not only for identification in OAL but also for the specific treatment with antibiotics. The recent molecular and cultural evidence of C. trachomatis in patients with OAL, seems to suggest that also this pathogen may contribute to pathogenesis of such lymphoma. The potential application of bacteria-eradicating therapy at local and systemic level may ultimately result in safer and more efficient therapeutic option for patients affected by these malignancies. Moreover, a close collaboration between experts in ophthalmology, infectious diseases and hematology will help, in the future, to effectively manage this disease. This review attempts to weigh the currently available evidence regarding the role that Chlamydia play in development of OAL and focuses on patients with OAL observed at our Institution.

Share and Cite:

C. Contini, S. Seraceni, M. Maritati, F. Cavazzini and P. Perri, "Role of Chlamydia in the Development of Ocular Adnexal Lymphoma," Journal of Cancer Therapy, Vol. 4 No. 2, 2013, pp. 662-677. doi: 10.4236/jct.2013.42082.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] C. E. Margo and Z. D. Mulla, “Malignant Tumours of the Orbit: Analysis of the Floridacancer Registry,” Ophthalmology, Vol. 105, No. 1, 1998, pp. 185-190. doi:10.1016/S0161-6420(98)92107-8
[2] K. Sasai, H. Yamabe, Y. Dodo, et al., “Non-Hodgkin’s Lymphoma of the Ocular Adnexa,” Acta Oncologica, Vol. 40, No. 4, 2001, pp. 485-90. doi:10.1080/028418601750288217
[3] J. I. Wyatt and B. J. Rathbone, “Immune Response of the Gastric Mucosa to Campylobacter pylori,” Scandinavian Journal of Gastroenterology, Vol. 23, No. s142, 1988, pp. 44-49. doi:10.3109/0036 5528809091712
[4] V. Conteduca, D. Sansonno, G. Lauletta, S. Russi, G. Ingravallo and F. Dammacco, “H. pylori Infection and Gastric Cancer: State of the Art,” International Journal of Oncology, Vol. 42, No. 1, 2013, pp. 5-18. doi:10.3892/ijo.2012.1701
[5] U. Dutta, P. K. Garg, R. Kumar and R. K. Tandon, “Typhoid Carriers among Patients with Gallstones Are at Increased Risk for Carcinoma of the Gallbladder,” The American Journal of Gastroenterology, Vol. 95, No. 3, 2000, pp. 784-787. doi:10.1111/j.1572-0241.2000.01860.x
[6] L. Johnson, E. Wirotsko, W. Wirotsko, et al., “Mycoplasma-Like Organisms in Hodkin’s Disease,” The Lancet, Vol. 347, No. 9005, 1996, pp. 901-902. doi:10.1016/S0140-6736(96)91381-1
[7] D. N. Slater, “Borreliaburgdorferi-Associated Primary Cutaneous B-Cell Lymphoma,” Histopathology, Vol. 38, No. 1, 2001, pp. 73-77. doi:10.1046/j.1365-2559.2001.01041.x
[8] A. J. Ferreri, M. Guidoboni, M. Ponzoni, et al., “Evidence for an Association between Chlamydia psittaci and Ocular Adnexal Lymphoma,” Journal of the National Cancer Institute, Vol. 96, No. 8, 2004, pp. 586-594. doi:10.1093/jnci/djh102
[9] U. Dreses-Werringloer, I. Padubrin, B. Juargens-Saathoff, et al., “Persistence of Chlamydia trachomatis Is Induced by Ciprofloxacin and Ofloxacin in Vitro,” Antimicrobial Agents and Chemotherapy, Vol. 44, No. 12, 2000, pp. 3288-3297.
[10] A. Husain, D. Roberts, B. Pro, et al., “Meta-Analyses of the Association between Chlamydia psittaci and Ocular Adnexal Lymphoma and the Response of Ocular Adnexal Lymphoma to Antibiotics,” Cancer, Vol. 110, No. 4, 2007, pp. 809-815. doi:10.1002/cncr.22843
[11] C. Jenkins, G. E. Rose, C. Bunce, et al., “Histological Features of Ocular Adnexal Lymphoma (REAL Classification) and Their Association with Patient Morbidity and Survival,” British Journal of Ophthalmology, Vol. 84, No. 8, 2000, pp. 907-913. doi:10.1136/bjo.84.8.907
[12] P. G. Isaacson and M.-Q. Du, “MALT Lymphoma: From Morphology to Molecules,” Nature Reviews Cancer, Vol. 4, No. 8, 2004, pp. 644-653. doi:10.1038/nrc1409
[13] M. Guidoboni, A.J. Ferreri, M. Ponzoni, et al., “Infectious Agents in Mucosa-Associated Lymphoid Tissue-Type Lymphomas: Pathogenic Role and Therapeutic Perspectives,” Clinical Lymphoma and Myeloma, Vol. 6, No. 4, 2006, pp. 289-300. doi:10.3816/CLM.2006.n.003
[14] K. Tanimoto, A. Kaneko, S. Suzuki, et al., “Primary Ocular Adnexal MALT Lymphoma: A Long-Term Follow-Up Study of 114 Patients,” Japanese Journal of Clinical Oncology, Vol. 37, No. 5, 2007, pp. 337-344.
[15] J. Meunier, L. L.-L. Rouic, A. Vincent-Salomon, et al., “Ophthalmologic and Intraocular Non-Hodgkin’s Lymphoma: A Large Single Centre Study of Initial Characteristics, Natural History, and Prognostic Factors,” Hematological Oncology, Vol. 22, No. 4, 2004, pp. 143-158. doi:10.1002/hon.741
[16] E. Y. Cho, J. J. Han, H. J. Ree, et al., “Clinicopathologic Analysis of Ocular Adnexal Lymphomas: Extranodal Marginal Zone B-Cell Lymphoma Constitutes the Vast Majority of Ocular Lymphomas among Koreans and Affects Younger Patients,” American Journal of Hematoogyl, Vol. 73, No. 2, 2003, pp. 87-96. doi:10.1002/ajh.10332
[17] R. Moslehi, S. S. Devesa, C. Schairer and J. F. Fraumeni Jr., “Rapidly Increasing Incidence of Ocular Non-Hodgkin Lymphoma,” Journal of the National Cancer Institute, Vol. 98, No. 11, 2006, pp. 936-939. doi:10.1093/jnci/djj248
[18] A. J. Ferreri, R. Dolcetti, S. Magnino, et al., “Chlamydial Infection: The Link with Ocular Adnexal Lymphomas,” Nature Reviews Clinical Oncology, Vol. 6, No. 11, 2009, pp. 658-669.
[19] D. Decaudin, P. de Cremoux, A. Vincent-Salomon, et al., “Ocular Adnexal Lymphoma: A Review of Clinicopathologic Features and Treatment Options,” Blood, Vol. 108, No. 5, 2006, pp. 1451-1460. doi:10.1182/blood-2006-02-005017
[20] V. Verma, D. Shen, P. C. Sieving, et al., “The Role of Infectious Agents in the Etiology of Ocular Adnexal Neoplasia,” Survey of Ophthalmology, Vol. 53, No. 4, 2008, pp. 312-331. doi:10.1016/j.survophthal.2008.04.008
[21] S. Bhatia, A. C. Paulino, J. M. Buatti, et al., “Curative Radiotherapy for Primary Orbital Lymphoma,” International Journal of Radiation Oncology*Biology*Physics, Vol. 54, No. 3, 2002, pp. 818-23. doi:10.1016/S0360-3016(02)02966-8
[22] S. Martinet, M. Ozsahin, Y. Belkacémi, et al., “Outcome and Prognostic Factors in Orbital Lymphoma: A Rare Cancer Network Study on 90 Consecutive Patients Treated with Radiotherapy Mar,” International Journal of Radiation Oncology*Biology*Physics, Vol. 55, No. 4, 2003, pp. 892-898. doi:10.1016/S0360-3016(02)04159-7
[23] T. Uno, K. Isobe, N. Shikama, et al., “Radiotherapy for Extranodal, Marginal Zone, B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue Originating in the Ocular Adnexa: A Multiinstitutional, Retrospective Review of 50 Patients,” Cancer, Vol. 98, No. 4, 2003, pp. 865-871. doi:10.1002/cncr.11539
[24] F. Collina, A. De Chiara, A. De Renzo, et al., “Chlamydia psittaci in Ocular Adnexa MALT Lymphoma: A Possible Role in Lymphomagenesis and a Different Geographical Distribution,” Infectious Agents and Cancer, Vol. 7, No. 8, 2012. doi:10.1186/1750-9378-7-8
[25] A. J. Ferreri, A. Assanelli, R. Crocchiolo, et al., “Therapeutic Management of Ocular Adnexal MALT Lymphoma,” Expert Opinion on Pharmacotherapy, Vol. 8, No. 8, 2007, pp. 1073-1083. doi:10.1517/14656566.8.8.1073
[26] B. Streubel, I. Simonitsch-Klupp, L. Mu?llauer, et al., “Variable Frequencies of MALT Lymphoma-Associated Genetic Aberrations in MALT Lymphomas of Different Sites,” Leucemia, Vol. 18, No. 10, 2004, pp. 1722-1726.
[27] H. Inagaki, “Mucosa-Associated Lymphoid Tissue Lymphoma: Molecular Pathogenesis and Clinicopathological Significance,” Pathology International, Vol. 57, No. 8, 2007, pp. 474-484.
[28] P. C. Lucas, M. Yonezumi, N. Inohara, et al., “Bcl10 and MALT1, Independent Targets of Chromosomal Translocation in MALT Lymphoma, Cooperate in a Novel NF-B Signalling Pathway,” Journal of Biology and Chemistry, Vol. 276, No. 22, 2001, pp. 19012-19019. doi:10.1074/jbc.M009984200
[29] U. Novak, A. Rinaldi, I. Kwee, et al., “The NF-{kappa}B Negative Regulator TNFAIP3 (A20) Is Inactivated by Somatic Mutations and Genomic Deletions in Marginal Zone Lymphomas,” Blood, Vol. 113, No. 20, 2009, pp. 4918-4921. doi:10.1182/blood-2008-08-174110
[30] K. Honma, S. Tsuzuki, M. Nakagawa et al., “TNF-AIP3 Is the Target Gene of Chromosome Band 6q23.3-q24.1 Loss in Ocular Adnexal Marginal Zone B Cell Lymphoma,” Genes Chromosomes and Cancer, Vol. 47, No. 1, 2008, pp. 1-7. doi:10.1002/gcc.20499
[31] P. A. McKelvie, “Ocular Adnexal Lymphomas: A Review,” Advance in Anatomic Pathology, Vol. 17, No. 4, 2010, pp. 251-261. doi:10.1097/PAP.0b013e3181e4abdb
[32] K. D. Everett, R. M. Bush and A. A. Andersen, “Emended Description of the Order Chlamydiales, Proposal of Parachlamydiaceae fam. nov. and Simkaniaceae fam. nov., Each Containing Onemonotypic Genus, Revised Taxonomy of the Family Chlamydiaceae, Including A New Genus and Five New Species, and Standards for the Identification of Organisms,” International Journal of Systematic and Evolutionary Microbiology, Vol. 49, No. 2, 1999, pp. 415-440. doi:10.1099/00207713-49-2-415
[33] A. Dautry-Varsat, A. Subtil and T. Hackstadt, “Recent Insights into the Mechanisms of Chlamydia Entry,” Celularl Microbiology, Vol. 7, No. 12, 2005, pp. 1714-1722.
[34] F. N. Wuppermann, K. M?lleken, M. Julien, et al., “Chlamydia pneumonia GroEL1 Protein Is Cell Surface Associated and Required for Infection of HEp-2 Cells,” Journal of Bacteriology, Vol. 190, No. 10, 2008, pp. 3757-3767. doi:10.1128/JB.01638-07
[35] J. W. Moulder, “Interaction of Chlamydiae and Host Cells in Vitro,” Microbiological Reviews, Vol. 55, No. 1, 1991, pp. 143-190.
[36] H. C. Gérard, B. Krausse-Opatz, Z. Wang, et al., “Expression of Chlamydia trachomatis Genes Encoding Products Required for DNA Synthesis and Cell Division during Active versus Persistent Infection,” Molecular Microbiology, Vol. 41, No. 3, 2001, pp. 731-741. doi:10.1046/j.1365-2958.2001.02550.x
[37] R. S. Stephens, “The Cellular Paradigm of Chlamydial Pathogenesis,” Trends in Microbiology, Vol. 11, No. 1, 2003, pp. 44-51. doi:10.1016/S0966-842X(02)00011-2
[38] R. J. Hogan, S. A, Mathews, S. Mukhopadhyay, et al., “Chlamydial Persistence: Beyond the Biphasic Paradigm,” Infection and Immunity, Vol. 72, No. 4, 2004, pp. 1843-1855. doi:10.1128/IAI.72.4.1843-1855.2004
[39] A. Kutlin, C. Flegg, D. Stenzel, et al., “Ultrastructural Study of Chlamdyia pneumoniae in a Continuous-Infection Model,” Journal of Clinical Microbiology, Vol. 39, No. 10, 2001, pp. 3721-3723. doi:10.1128/JCM.39.10.3721-3723.2001
[40] D. Dean and W. C. Powers, “Persistent Chlamydia trachomatis Infections Resist Apoptotic Stimuli,” Infection and Immunity, Vol. 69, No. 4, pp. 2442-2447.
[41] W. L. Beatty, R. P. Morrison and G. I. Byrne, “Persistent Chlamydiae: From Cell Culture to a Paradigm for Chlamydial Pathogenesis,” Microbiological Reviews, Vol. 58, No. 4, 1994, pp. 686-699.
[42] J. E. Raulston, “Response of Chlamydia trachomatis Serovar E to Iron Restriction in Vitro and Evidence for Iron-Regulated Chlamydial Proteins,” Infection and Immunity, Vol. 65, No. 11, 1997, pp. 4539-4547.
[43] E. A. Sueltenfuss and M. Pollard, “Cytochemical Assay of Interferon Produced by Duck Hepatitis Virus,” Science, Vol. 139, No. 3555, 1963, pp. 595-596. doi:10.1126/science.139.3555.595
[44] L. M. Sardinia, E. Segal and D. Ganem, “Developmental Regulation of the Cysteine-Rich Outermembrane Proteins of Murine Chlamydia trachomatis,” Journal of General Microbiology, Vol. 134, No. 4, 1988, pp. 997-1004.
[45] S. Bas, L. Neff, M. Vuillet, et al., “The Proinflammatory Cytokine Response to Chlamydia trachomatis Elementary Bodies in Human Macrophages Is Partly Mediated by A Lipoprotein, the Macrophage Infectivity Potentiator, through TLR2/TLR1/TLR6 and CD14,” The Journal of Immunology, Vol. 180, No. 2, 2008, pp. 1158-1168.
[46] Y. Naiki, K. S. Michelsen, N. W. Schr?der, et al., ”MyD-88 Is Pivotal for the Early Inflammatory Response and Subsequent Bacterial Clearance and Survival in a Mouse Model of Chlamydia pneumoniae Pneumonia,” The Journal of Biological Chemistry, Vol. 280, No. 32, 2005, pp. 29242-29249. doi:10.1074/jbc.M503225200
[47] J. Peters, D. P. Wilson, G. Myers, et al., “Type III Secretion à la Chlamydia,” Trends in Microbiology, Vol. 15, No. 6, 2007, pp. 241-251. doi:10.1016/j.tim.2007.04.005
[48] G. M. Zhong, “Killing Me Softly: Chlamydial Use of Proteolysis for Evading Host Defenses,” Trends in Microbiology, Vol. 17, No. 10, 2009, pp. 467-474. doi:10.1016/j.tim.2009.07.007
[49] K. Manavi, “A Review on Infection with Chlamydia trachomatis,” Best Practice & Research Clinical Obstetrics & Gynaecology, Vol. 20, No. 6, 2006, pp. 941-951. doi:10.1016/j.bpobgyn.2006.06.003
[50] J. Schachter, E. C. Hill, E. B. King, et al., “Chlamydial Infection in Women with Cervical Dysplasia,” American Journal of Obstetrics and Gynecology, Vol. 123, No. 7, 1975, pp. 753-757.
[51] J. T. Quirk and J. M. Kupinski, “Chronic Infection, Inflammation, and Epithelial Ovarian Cancer,” Medical Hypotheses, Vol. 57, No. 4, 2001, pp. 426-428. doi:10.1054/mehy.2001.1326
[52] A. Olejek, I. Kozak-Darmas, S. Kellas-Sleczka, et al., “Chlamydia trachomatis Infection in Women with Lichen Sclerosus Vulvae and Vulvar Cancer,” Neuro Endocrinology, Vol. 30, No. 5, 2009, pp. 671-674.
[53] K. L. Millman, S. Tavare, D. Dean, “Recombination in the OmpA Gene but Not the OmcB Gene of Chlamydia Contributes to Serovar-Specific Differences in Tissue Tropism, Immune Surveillance, and Persistence of the Organism,” Journal of Bacteriology, Vol. 183, No. 20, 2001, pp. 5997-6008. doi:10.1128/JB.183.20.5997-6008.2001
[54] F. Cappello, F. C. de Macario, V. Di Felice, et al., “Chlamydia trachomatis Infection and Anti-Hsp60 Immunity: The Two Sides of the Coin,” PLoS Pathogens, Vol. 5, No. 8, 2009, p. e1000552.
[55] M. Kauppinen and P. Saikku, “Pneumonia Due to Chlamydia Pneumoniae: Prevalence, Clinical Features, Diagnosis, and Treatment,” Clinical Infectious Diseases, Vol. 21, Suppl. 3, 1995, pp. S244-S252. doi:10.1093/clind/21.Supplement_3.S244
[56] C. C. Kuo, L. A. Jackson, L. A. Campbell, et al., “Chlamydia pneumoniae (TWAR),” Clinical Microbiology Reviews, Vol. 8, No. 4, 1995, pp. 451-461.
[57] P. Saikku, M. Leinonen, K. Mattila, et al., “Serological Evidence of an Association of a Novel Chlamydia, TWAR, with Chronic Coronary Heart Disease and Acute Myocardial Infarction,” The Lancet, Vol. 332, No. 8618, 1988, pp. 983-986. doi:10.1016/S0140-6736(88)90741-6
[58] M. S. Elkind, I. F. Lin, J. T. Grayston, et al., “Chlamydia pneumoniae and the Risk of First Ischemic Stroke: The Northern Manhattan Stroke Study,” Stroke, Vol. 31, No. 7, 2000, pp. 1521-1525. doi:10.1161/01.STR.31.7.1521
[59] S. Sriram, A. Ljunggren-Rose, S. Y. Yao, et al., “Detection of Chlamydial Bodies and Antigens in the Central Nervous System of Patients with Multiple Sclerosis,” The Journal of Infectious Diseases, Vol. 192, No. 7, 2005, pp. 1219-1228. doi:10.1086/431518
[60] C. Contini, R. Cultrera, S. Seraceni, et al., “Cerebrospinal Fluid Molecular Demonstration of Chlamydia pneumoniae DNA Is Associated to Clinical and Brain Magnetic Resonance Imaging Activity in a Subset of Patients with Relapsing-Remitting Multiple Sclerosis,” Multiple Sclerosis Journal, Vol. 10, No. 4, 2004, pp. 360-369. doi:10.1191/1352458504ms1049oa
[61] C. Contini, S. Seraceni, et al., “Chlamydophila pneumoniae Infection and Its Role in Neurological Disorders,” Interdisciplinary Perspectives Infectious Diseases, Vol. 2010, 2010, Article ID: 273573.
[62] A. K. Chaturvedi, C. A. Gaydos, P. Agreda, et al., “Chlamydia pneumoniae Infection and Risk for Lung Cancer,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 19, No. 6, 2010, p. 1505. doi:10.1158/1055-9965.EPI-09-1261
[63] A. J. Littman, L. A. Jackson and T. L. Vaughan, “Chlamydia pneumoniae and Lung Cancer: Epidemiologic Evidence,” Cancer Epidemiology Biomarkers & Prevention, Vol. 14, No. 4, 2005, pp. 773-778. doi:10.1158/1055-9965.EPI-04-0599
[64] B. Kocazeybek, “Chronic Chlamydophila pneumoniae Infection in Lung Cancer, a Risk Factor: A Case-Control Study,” Journal of Medical Microbiology, Vol. 52, No. 8, 2003, pp. 721-726. doi:10.1099/jmm.0.04845-0
[65] P. Zhan, L. J. Suo, Q. Qian, et al., “Chlamydia pneumoniae Infection and Lung Cancer Risk: Meta-Analysis,” European Journal of Cancer, Vol. 47, No. 5, 2011, pp. 742-747. doi:10.1016/j.ejca.2010.11.003
[66] C. Contini and S. Seraceni, “Chlamydial Disease: A Cross-Road between Chronic Infection and Development of Cancer,” In: A. A. Khan, Bacteria and Cancer, Chapter 4, Springer Science, Berlin, 2012, pp. 79-116. doi:10.1007/978-94-007-2585-0_4
[67] T. J. Bodetti, P. Timms, “Detection of Chlamydia pneumoniae DNA and Antigen in the Circulating Mononuclear Cell Fractions of Humans and Koalas,” Infection and Immunity, Vol. 68, No. 5, 2000, 2744-2747. doi:10.1128/IAI.68.5.2744-2747.2000
[68] C. Contini, S. Seraceni, M. Castellazzi, et al., “Chlamydophila pneumoniae DNA and mRNA Transcript Levels in Peripheral Blood Mononuclear Cells and Cerebrospinal Fluid of Patients with Multiple Sclerosis,” Neuroscience Research, Vol. 62, No. 1, 2008, pp. 58-61. doi:10.1016/j. neures.2008.05.003
[69] S. Haranaga, H. Yamaguchi, H. Friedman, et al., “Chlamydia pneumoniae Infects and Multiplies in Lymphocytes in Vitro,” Infection and Immunity, Vol. 69, No. 12, 2001, pp. 7753-7759. doi:10.1128/IAI.69.12.7753-7759.2001
[70] G. Van Zandergen, J. Gieffers, H. Kothe, et al., “Chlamydia pneumoniae Multiply in Neutrophil Granulocytes and Delay Their Spontaneous Apoptosis,” The Journal of Immunology, Vol. 172, No. 3, 2004, pp. 1768-1776.
[71] C. Yucesan and S. Sriram, “Chlamydia pneumoniae Infection of the Central Nervous System,” Current OpinNeurology, Vol. 14, No. 3, 2001, pp. 355-359. doi:10.1097/00019052-200106000-00015
[72] L. Rasanen, M. Lehto, I. Jokinen, et al., “Polyclonal Antibody Formation of Human Lymphocytes to Bacterial Components,” Immunology, Vol. 58, No. 4, 1986, pp. 577-581.
[73] G. I. Byrne and D. M. Ojcius, “Chlamydia and Apoptosis: Life and Death Decisions of an Intracellular Pathogen,” Nature Reviews Microbiology, Vol. 2, No. 10, 2004, pp. 802-808. doi:10.1038/ nrmicro1007
[74] L. Hanna, L. Schmidt, M. Sharp, et al., “Human CellMediated Immune Responses to Chlamydial Antigens,” Infection and Immunity, Vol. 23, No. 2, 1979, pp. 412-417.
[75] I. Miyairi and G. I. Byrne, “Chlamydia and Programmed Cell Death,” Current Opinion in Microbiology, Vol. 9, No. 1, 2006, pp. 102-108. doi:10.1016/j.mib.2005.12.004
[76] A. Aigelsreiter, T. Gerlza, A. J. Deutsch, et al., “Chlamydia psittaci Infection in Nongastrointestinal Extranodal MALT Lymphomas and Their Precursor Lesions,” American Society for Clinical Pathology, Vol. 135, No. 1, 2011, pp. 70-75. doi:10.1309/AJCPXMDRT1SY6KIV
[77] J. E. Sykes, G. A. Anderson, V. P. Studdert, et al., “Prevalence of Feline Chlamydia psittaci and Feline Herpesvirus 1 in Cats with Upper Respiratory Tract Disease,” Journal of Veterinary Internal Medicine, Vol. 13, No. 3, 1999, pp. 153-162. doi:10.1111/j.1939-1676.1999.tb02172.x
[78] A. J. Ferreri, M. Ponzoni, M. Guidoboni, et al., “Regression of Ocular Adnexal Lymphoma after Chlamydia psittaci—Eradicating Antibiotic Therapy,” Journal of Clinical Oncology, Vol. 23, No. 22, 2005, pp. 5067-5073. doi:10.1200/JCO.2005.07.083
[79] A. J. Ferreri, R. Dolcetti, G. P. Dognini, et al., “Chlamydophila psittaci Is Viable and Infectious in the Conjunctiva and Peripheral Blood of Patients with Ocular Adnexal Lymphoma: Results of a Single-Center Prospective Case-Control Study,” International Journal of Cancer, Vol. 123, No. 5, 2008, pp. 1089-1093. doi:10.1002/ijc.23596
[80] M. F. Rosado, G. E. Byrne Jr., F. Ding, et al., “Ocular Adnexal Lymphoma: A Clinicopathological Study of a Large Cohort of Patients with No Evidence for an Association with Chlamydia psittaci,” Blood, Vol. 107, No. 2, 2006, pp. 467-472. doi:10.1182/blood-2005-06-2332
[81] M. Q. Du, “MALT Lymphoma: Recent Advances in Aetiology and Molecular Genetics,” Journal of Clinical and Experimental Hematopathology, Vol. 47, No. 2, 2007, pp. 31-42. doi:10.3960/jslrt.47.31
[82] C. Yoo, M. H. Ryu, J. Huh, et al., “Chlamydia psittaci Infection and Clinicopathologic Analysis of Ocular Adnexal Lymphomas in Korea,” American Journal of Hematology, Vol. 82, No. 9, 2007, pp. 821-823. doi:10.1002/ajh.20962
[83] M. Daibata, Y. Nemoto, K. Togitani, et al., “Absence of Chlamydia psittaci in Ocular Adnexal Lymphoma from Japanese Patients,” British Journal of Haematology, Vol. 132, No. 5, 2006, pp. 651-652. doi:10.1111/j.1365-2141.2005.05943.x
[84] Y. C. Liu, J. H. Ohyashiki, Y. Ito, et al., “Chlamydia psittaci in Ocular Adnexal Lymphoma: Japanese Experience,” Leukemia Research, Vol. 30, No. 12, 2006, pp. 1587-1589. doi:10.1016/j. leukres.2006.01.015
[85] M. M. Mulder, E. R. Heddema, Y. Pannekoek, et al., “No Evidence for an Association of Ocular Adnexal Lymphoma with Chlamydia psittaci in a Cohort of Patients from the Netherlands,” Leukemia Research, Vol. 30, No. 10, 2006, pp. 1305-1307. doi:10.1016/j.leukres.2005.12.003
[86] E. Chanudet, Y. Zhou, C. M. Bacon, et al., “Chlamydia psittaci Is Variably Associated with Ocular Adnexal MALT Lymphoma in Different Geographical Regions,” The Journal of Pathology, Vol. 209, No. 3, 2006, pp. 344-351. doi:10.1002/path.1984
[87] E. Gracia, P. Froesch, L. Mazzucchelli, et al., “Low Prevalence of Chlamydia psittaci in Ocular Adnexal Lymphomas from Cuban Patients,” Leukemia & Lymphoma, Vol. 48, No. 1, 2007, pp. 104-108. doi:10.1080/10428190600908174
[88] A. Carugi, A. Onnis, G. Antonicelli, et al., “Geographic Variation and Environmental Conditions as Cofactors in Chlamydia psittaci Association with Ocular Adnexal Lymphomas: A Comparison between Italian and African Samples,” Hematological Oncology, Vol. 28, 2010, pp. 20-26.
[89] R. L. Vargas, E. Fallone, R. E. Felgar, et al., “Is There an Association between Ocular Adnexal Lymphoma and Infection with Chlamydia psittaci? The University of Rochester Experience,” Leukemia Research, Vol. 30, No. 5, 2006, pp. 547-551. doi:10.1016/j.leukres.2005.09.012
[90] M. Ponzoni, A. J. Ferreri, M. Guidoboni, et al., “Chlamydia Infection and Lymphomas: Association beyond Ocular Adnexal Lymphomas Highlighted by Multiple Detection Methods,” Clinical Cancer Research, Vol. 14, No. 18, 2008, pp. 5794-5800. doi:10.1158/1078-0432.CCR-08-0676
[91] G. Madico, T. C. Quinn, J. Boman, et al., “Touchdown Enzyme Time Release-PCR for Detection and Identification of Chlamydia trachomatis, C. pneumoniae, and C. psittaci Using the 16S and 16S-23S Spacer rRNA Genes,” Journal of Clinical Microbiology, Vol. 38, No. 3, 2000, pp. 1085-1093.
[92] M. Ponzoni, A. J. Ferreri, C. Dogliosi, et al., “Unconventional Therapies in Ocular Adnexal Lymphomas,” Expert Review of Anticancer Therapy, Vol. 10, No. 9, 2010, pp. 1341-1343. doi:10.1586/era.10.125
[93] D. Shen, H. K. Yuen, D. A. Galita, et al., “Detection of Chlamydia pneumoniae in a Bilateral Orbital MucosaAssociated Lymphoid Tissue Lymphoma,” American Journal of Ophthalmology, Vol. 141, No. 6, 2006, pp. 1162-1163. doi:10.1016/j.ajo.2006.01.067
[94] C. C. Chan, D. Shen, M. Mochizuki, et al., “Detection of Helicobacter pylori and Chlamydia pneumoniae Genes in Primary Orbital Lymphoma,” Transactions of American Ophthalmological Society, Vol. 104, 2006, pp. 62-70.
[95] Centers for Disease Control and Prevention, “Sexually Transmitted Diseases Surveillance,”
[96] J. Schachter, “Infection and Disease Epidemiology,” In: R. S. Stephens, Ed., Chlamydia: Intracellular Biology, Pathogenesis and Immunity, ASM Press, Washington DC, 1999, pp. 139-169.
[97] H. C. Gérard, J. A. Whittum-Hudson, J. D. Carter and A. P. Hudson, “Molecular Biology of Infectious Agents in Chronic Arthritis,” Rheumatic Disease Clinics of North America, Vol. 35, No. 1, 2009, pp. 1-19. doi:10.1016/j.rdc.2009.03.011
[98] R. V. Schoborg, “Chlamydia Persistence—A Tool to Dissect Chlamydia-Host Interactions,” Microbes and Infection, Vol. 13, No. 7, 2011, pp. 649-662. doi:10.1016/j.micinf.2011.03.004
[99] C. Contini, S. Seraceni, S. Carradori, et al., “Identification of Chlamydia trachomatis in a Patient with Ocular Lymphoma,” American Journal of Hematology, Vol. 84, No. 9, 2009, pp. 597-599. doi:10.1002/ajh.21477
[100] C. Contini, E. Caselli, A. Borghi, et al., “Evidence of Chlamydophila pneumoniae and Human Herpesvirus 8 in Primary Cutaneous Anaplastic Large-Cell Lymphoma,” 23rd ECCMID, Berlin, 27-30 April 2013, Abstract N. 2255.
[101] H. C. Gerard, J. A. Whittum-Hudson, H. R. Schumacher et al., “Differential Expression of Three Chlamydia trachomatis Hsp60-Encoding Genes in Active vs. Persistentinfections,” Microbial Pathogenesis, Vol. 36, No. 1, 2004, 35-39. doi:10.1016/j.micpath.2003.08.005
[102] J. M. Pruckler, N. Masse, V. A. Stevens, et al., “Optimizing Culture of Chlamydia pneumonia by Using Multiple Centrifugations,” Journal of Clinical Microbiology, Vol. 37, No. 10, 1999, pp. 3399-3401.
[103] S. H. Swerdlow, E. Campo and N. L. Harris, “The WHO Classification of Tumours of the Haemopoietic and Lymphoid Tissues,” IARC Press, Lyon, 2008.
[104] A. J. Ferreri, R. Dolcetti, M. Q. Due, et al., “Ocular Adnexal MALT Lymphoma: An Intriguing Model for Antigen-Driven Lymphomagenesis and Microbial Targeted Therapy,” Annals of Oncology, Vol. 19, No. 5, 2007, pp. 835-846. doi:10.1093/annonc/mdm513
[105] V. M. Cohen, “Treatment Options for Ocular Adnexal Lymphoma (OAL),” Clinical Ophthalmology, Vol. 3, No. 2009, 2009, pp. 689-692.
[106] C. Heinz, H. Merz, M. Nieschalk, et al., “Rituximab for the Treatment of Extranodal Marginal Zone B-Cell Lymphoma of the Lacrimal Gland,” British Journal of Ophthalmology, Vol. 91, No. 11, 2007, pp. 1563-1564. doi:10.1136/bjo.2007.115626
[107] B. Esmaeli, P. McLaughlin, B. Pro, et al., “Prospective Trial of Targeted Radioimmunotherapy with Y-90 Ibritumomabtiuxetan (Zevalin) for Front-Line Treatment of Early-Stage Extranodal Indolent Ocular Adnexal Lymphoma,” Annals of Oncology, Vol. 20, No. 4, 2009, pp. 709-714. doi:10.1093/ annonc/mdn692
[108] B. Gru?nberger, W. Hauff, J. Lukas, et al., “ ‘Blind’ Antibiotic Treatment Targeting Chlamydia Is Not Effective in Patients with MALT Lymphoma of the Ocular Adnexa,” Annals of Oncology, Vol. 17, No. 3, 2006, pp. 484-487.
[109] A. J. Ferreri, M. Ponzoni, M. Guidoboni, et al., “Bacteria-Eradicating Therapy with Doxycycline in Ocular Adnexal MALT Lymphoma: A Multicenter Prospective Trial,” Journal of the national institute, Vol. 98, No. 19, 2006, pp. 1375-1382. doi:10.1093/jnci/djj373
[110] J. M. Matthews, L. I. Moreno and J. Dennis, “Ocular Adnexal Lymphoma: No Evidence for Bacterial DNA Associated with Lymphoma Pathogenesis,” British Journal of Haematology, Vol. 142, No. 2, 2008, pp. 246-249. doi:10.1111/j.1365-2141.2008.07112.x
[111] S. Govi, R. Dolcetti, M. Ponzoni, et al., “A Phase II Trial to Investigate the Link with Infectious Agents in Ocular Adnexal Marginal Zone Lymphoma, Especially with Chlamydia Species, and the Antineoplastic Effects of Doxycycline,” Haematologica, Vol. 95, Suppl. 2, 2010, p. 282.
[112] T. Matsumoto and M. Iida, “Extra-Gastric Lymphoma of MALT Type and H. pylori Eradication,” Nippon Rinsho, Vol. 63, Suppl. 1, 2005, pp. 308-311.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.